Clinical Trial Detail

NCT ID NCT03513484
Title Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Northwestern University
Indications

acute myeloid leukemia

Therapies

Azacitidine + Nintedanib

Age Groups: adult senior

Additional content available in CKB BOOST